TABLE 1.
Trail | Year | Patients | Setting | Study design | Agent dose | Main clinical results |
---|---|---|---|---|---|---|
LoDoCo42 | 2013 | 532 | Stable CAD (n = 282), controls (n = 250) | Single‐blind RCT | Colchicine 0.5 mg/d | In patients with stable coronary disease, low dose of colchicine (0.5 mg per d) seems to effectively prevent cardiovascular events |
CANTOS40 | 2017 | 10061 | MI ≥ 30 d (n = 6717), controls (n = 3344) | Double‐blind, placebo controlled RCT | Canakinumab 50 mg, 150 mg, 300 mg/3 mo | 150 mg of Canakinumab every 3 mo resulted in a significantly lower incidence of recurrent cardiovascular events than placebo, regardless of the reduction in blood lipid levels |
CIRT47 | 2019 | 4786 | Resent MI (n = 2391), controls (n = 2395) | Double‐blind, placebo controlled RCT | Methotrexate 15–20 mg/wk | Low‐dose methotrexate does not reduce IL−1β, IL−6 or C‐reactive protein levels, and does not cause fewer cardiovascular events than placebo |
COLCOT48 | 2019 | 4745 | Resent MI (n = 2366), controls (n = 2379) | Double‐blind, placebo controlled RCT | Colchicine 0.5 mg/d | 0.5 mg of colchicine per day has a much lower rate of ischemic cardiovascular events than placebo |
COPS45 | 2020 | 795 | ACS and CAD (n = 396), controls (n = 399) | Double‐blind, placebo controlled RCT | Colchicine 1 mg/d for 1 mo, then 0.5 mg/day for 11 mo | The addition of colchicine to standard drug therapy has no significant effect on the cardiovascular outcome of ACS patients at 12 mo and is associated with a higher mortality rate |
LoDoCo243 | 2020 | 5522 | Stable CAD (n = 2762), controls (n = 2760) | Double‐blind, placebo controlled RCT | Colchicine 0.5 mg/d | Patients receiving 0.5 mg of colchicine per day had a significantly lower risk of cardiovascular events than patients receiving placebo |
Abbreviations: ACS, Acute coronary syndrome; CAD, coronary atherosclerotic disease; CANTOS, Canakinumab Anti‐inflammatory Thrombosis Outcome Study; CIRT, Cardiovascular Inflammation Reduction Trial; COLCOT, Colchicine Cardiovascular Outcomes Trial; COPS, The Australian COPS Trial; LoDoCo, the Low‐dose Colchicine trail; LoDoCo2, the Low‐dose Colchicine trail 2; MI, myocardial infraction; RCT, Redis Computed Tomography.